218 related articles for article (PubMed ID: 34337560)
1. A GPC2 antibody-drug conjugate is efficacious against neuroblastoma and small-cell lung cancer via binding a conformational epitope.
Raman S; Buongervino SN; Lane MV; Zhelev DV; Zhu Z; Cui H; Martinez B; Martinez D; Wang Y; Upton K; Patel K; Rathi KS; Navia CT; Harmon DB; Li Y; Pawel B; Dimitrov DS; Maris JM; Julien JP; Bosse KR
Cell Rep Med; 2021 Jul; 2(7):100344. PubMed ID: 34337560
[TBL] [Abstract][Full Text] [Related]
2. Identification of GPC2 as an Oncoprotein and Candidate Immunotherapeutic Target in High-Risk Neuroblastoma.
Bosse KR; Raman P; Zhu Z; Lane M; Martinez D; Heitzeneder S; Rathi KS; Kendsersky NM; Randall M; Donovan L; Morrissy S; Sussman RT; Zhelev DV; Feng Y; Wang Y; Hwang J; Lopez G; Harenza JL; Wei JS; Pawel B; Bhatti T; Santi M; Ganguly A; Khan J; Marra MA; Taylor MD; Dimitrov DS; Mackall CL; Maris JM
Cancer Cell; 2017 Sep; 32(3):295-309.e12. PubMed ID: 28898695
[TBL] [Abstract][Full Text] [Related]
3. GPC2 antibody-drug conjugate reprograms the neuroblastoma immune milieu to enhance macrophage-driven therapies.
Pascual-Pasto G; McIntyre B; Shraim R; Buongervino SN; Erbe AK; Zhelev DV; Sadirova S; Giudice AM; Martinez D; Garcia-Gerique L; Dimitrov DS; Sondel PM; Bosse KR
J Immunother Cancer; 2022 Dec; 10(12):. PubMed ID: 36460335
[TBL] [Abstract][Full Text] [Related]
4. Antibody-Drug Conjugate Efficacy in Neuroblastoma: Role of Payload, Resistance Mechanisms, Target Density, and Antibody Internalization.
Buongervino S; Lane MV; Garrigan E; Zhelev DV; Dimitrov DS; Bosse KR
Mol Cancer Ther; 2021 Nov; 20(11):2228-2239. PubMed ID: 34465595
[TBL] [Abstract][Full Text] [Related]
5. Therapeutically targeting glypican-2 via single-domain antibody-based chimeric antigen receptors and immunotoxins in neuroblastoma.
Li N; Fu H; Hewitt SM; Dimitrov DS; Ho M
Proc Natl Acad Sci U S A; 2017 Aug; 114(32):E6623-E6631. PubMed ID: 28739923
[TBL] [Abstract][Full Text] [Related]
6. Development of GPC2-directed chimeric antigen receptors using mRNA for pediatric brain tumors.
Foster JB; Griffin C; Rokita JL; Stern A; Brimley C; Rathi K; Lane MV; Buongervino SN; Smith T; Madsen PJ; Martinez D; Delaidelli A; Sorensen PH; Wechsler-Reya RJ; Karikó K; Storm PB; Barrett DM; Resnick AC; Maris JM; Bosse KR
J Immunother Cancer; 2022 Sep; 10(9):. PubMed ID: 36167467
[TBL] [Abstract][Full Text] [Related]
7. GPC2-CAR T cells tuned for low antigen density mediate potent activity against neuroblastoma without toxicity.
Heitzeneder S; Bosse KR; Zhu Z; Zhelev D; Majzner RG; Radosevich MT; Dhingra S; Sotillo E; Buongervino S; Pascual-Pasto G; Garrigan E; Xu P; Huang J; Salzer B; Delaidelli A; Raman S; Cui H; Martinez B; Bornheimer SJ; Sahaf B; Alag A; Fetahu IS; Hasselblatt M; Parker KR; Anbunathan H; Hwang J; Huang M; Sakamoto K; Lacayo NJ; Klysz DD; Theruvath J; Vilches-Moure JG; Satpathy AT; Chang HY; Lehner M; Taschner-Mandl S; Julien JP; Sorensen PH; Dimitrov DS; Maris JM; Mackall CL
Cancer Cell; 2022 Jan; 40(1):53-69.e9. PubMed ID: 34971569
[TBL] [Abstract][Full Text] [Related]
8. CAR T cells targeting tumor-associated exons of glypican 2 regress neuroblastoma in mice.
Li N; Torres MB; Spetz MR; Wang R; Peng L; Tian M; Dower CM; Nguyen R; Sun M; Tai CH; de Val N; Cachau R; Wu X; Hewitt SM; Kaplan RN; Khan J; St Croix B; Thiele CJ; Ho M
Cell Rep Med; 2021 Jun; 2(6):100297. PubMed ID: 34195677
[TBL] [Abstract][Full Text] [Related]
9. Evaluating
Lakes AL; An DD; Gauny SS; Ansoborlo C; Liang BH; Rees JA; McKnight KD; Karsunky H; Abergel RJ
Mol Pharm; 2020 Nov; 17(11):4270-4279. PubMed ID: 33044830
[TBL] [Abstract][Full Text] [Related]
10. Anti-glypican-1 antibody-drug conjugate exhibits potent preclinical antitumor activity against glypican-1 positive uterine cervical cancer.
Matsuzaki S; Serada S; Hiramatsu K; Nojima S; Matsuzaki S; Ueda Y; Ohkawara T; Mabuchi S; Fujimoto M; Morii E; Yoshino K; Kimura T; Naka T
Int J Cancer; 2018 Mar; 142(5):1056-1066. PubMed ID: 29055044
[TBL] [Abstract][Full Text] [Related]
11. Development of Glypican-2 Targeting Single-Domain Antibody CAR T Cells for Neuroblastoma.
Li N; Ho M
Methods Mol Biol; 2022; 2446():451-468. PubMed ID: 35157288
[TBL] [Abstract][Full Text] [Related]
12. Preclinical optimization of a GPC2-targeting CAR T-cell therapy for neuroblastoma.
Sun M; Cao Y; Okada R; Reyes-González JM; Stack HG; Qin H; Li N; Seibert C; Kelly MC; Ruppin E; Ho M; Thiele CJ; Nguyen R
J Immunother Cancer; 2023 Jan; 11(1):. PubMed ID: 36631162
[TBL] [Abstract][Full Text] [Related]
13. A glypican-1-targeted antibody-drug conjugate exhibits potent tumor growth inhibition in glypican-1-positive pancreatic cancer and esophageal squamous cell carcinoma.
Munekage E; Serada S; Tsujii S; Yokota K; Kiuchi K; Tominaga K; Fujimoto M; Kanda M; Uemura S; Namikawa T; Nomura T; Murakami I; Hanazaki K; Naka T
Neoplasia; 2021 Sep; 23(9):939-950. PubMed ID: 34332450
[TBL] [Abstract][Full Text] [Related]
14. Association between GPC2 polymorphisms and neuroblastoma risk in Chinese children.
Li M; Zhang X; Liu J; Zhou C; Miao L; He J; Wu H; Zhang R
J Clin Lab Anal; 2023 Mar; 37(5):e24866. PubMed ID: 36920409
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of the DLL3-targeting antibody-drug conjugate rovalpituzumab tesirine in preclinical models of neuroblastoma.
Krytska K; Casey CE; Pogoriler J; Martinez D; Rathi KS; Farrel A; Berko ER; Tsang M; Sano RR; Kendsersky N; Erickson SW; Teicher BA; Isse K; Saunders L; Smith MA; Maris JM; Mossé YP
Cancer Res Commun; 2022 Jul; 2(7):616-623. PubMed ID: 36381237
[TBL] [Abstract][Full Text] [Related]
16. GPC2 Is a Potential Diagnostic, Immunological, and Prognostic Biomarker in Pan-Cancer.
Chen G; Luo D; Zhong N; Li D; Zheng J; Liao H; Li Z; Lin X; Chen Q; Zhang C; Lu Y; Chan YT; Ren Q; Wang N; Feng Y
Front Immunol; 2022; 13():857308. PubMed ID: 35345673
[TBL] [Abstract][Full Text] [Related]
17. An antibody-drug conjugate directed to the ALK receptor demonstrates efficacy in preclinical models of neuroblastoma.
Sano R; Krytska K; Larmour CE; Raman P; Martinez D; Ligon GF; Lillquist JS; Cucchi U; Orsini P; Rizzi S; Pawel BR; Alvarado D; Mossé YP
Sci Transl Med; 2019 Mar; 11(483):. PubMed ID: 30867324
[TBL] [Abstract][Full Text] [Related]
18. MRE11 inhibition highlights a replication stress-dependent vulnerability of MYCN-driven tumors.
Petroni M; Sardina F; Infante P; Bartolazzi A; Locatelli E; Fabretti F; Di Giulio S; Capalbo C; Cardinali B; Coppa A; Tessitore A; Colicchia V; Sahùn Roncero M; Belardinilli F; Di Marcotullio L; Soddu S; Comes Franchini M; Petricci E; Gulino A; Giannini G
Cell Death Dis; 2018 Aug; 9(9):895. PubMed ID: 30166519
[TBL] [Abstract][Full Text] [Related]
19. ADCT-301, a Pyrrolobenzodiazepine (PBD) Dimer-Containing Antibody-Drug Conjugate (ADC) Targeting CD25-Expressing Hematological Malignancies.
Flynn MJ; Zammarchi F; Tyrer PC; Akarca AU; Janghra N; Britten CE; Havenith CE; Levy JN; Tiberghien A; Masterson LA; Barry C; D'Hooge F; Marafioti T; Parren PW; Williams DG; Howard PW; van Berkel PH; Hartley JA
Mol Cancer Ther; 2016 Nov; 15(11):2709-2721. PubMed ID: 27535974
[TBL] [Abstract][Full Text] [Related]
20. Anti-Glypican-1 Antibody-drug Conjugate as Potential Therapy Against Tumor Cells and Tumor Vasculature for Glypican-1-Positive Cholangiocarcinoma.
Yokota K; Serada S; Tsujii S; Toya K; Takahashi T; Matsunaga T; Fujimoto M; Uemura S; Namikawa T; Murakami I; Kobayashi S; Eguchi H; Doki Y; Hanazaki K; Naka T
Mol Cancer Ther; 2021 Sep; 20(9):1713-1722. PubMed ID: 34224365
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
